Published on January 14, 2020
All prostate cancer is not the same. Care is becoming more personalized, and new drugs and new ways of treating prostate cancer are being developed all the time. Dr. Ana Aparicio, from The University of Texas MD Anderson Cancer Center, shares news about their Prostate Cancer Moonshot research program, FDA approvals for enzalutamide (Xtandi), darolutamide (Nubeqa), apalutamide (Erleada) and what they mean for metastatic prostate cancer patients.
Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.